CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma
The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadié, M., Simonetti, A., Lutz, J.-M., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282632 · Cited by 977
Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00662-6 · Cited by 799
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002394 · Cited by 489
Smith, A., Crouch, S., Lax, S., Li, J., Painter, D., Howell, D., Patmore, R., Jack, A., & Roman, E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.94 · Cited by 424
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M., Wang, M., Arnason, J., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., et al. (2024) · Blood · doi:10.1182/blood.2023020854 · Cited by 189
Di Blasi, R., Le Gouill, S., Bachy, E., Cartron, G., Beauvais, D., Le Bras, F., Gros, F.-X., Choquet, S., Bories, P., Feugier, P., et al. (2022) · Blood · doi:10.1182/blood.2022016945 · Cited by 167
Maurer, M. J., Habermann, T. M., Shi, Q., Schmitz, N., Cunningham, D., Pfreundschuh, M. G., Seymour, J. F., Jaeger, U., Haïoun, C., Tilly, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy203 · Cited by 122
Roddie, C., Lekakis, L. J., Marzolini, M. A. V., Ramakrishnan, A., Zhang, Y., Hu, Y., Peddareddigari, V. G. R., Khokhar, N. Z., Chen, R. W., Basilico, S., et al. (2023) · Blood · doi:10.1182/blood.2022018598 · Cited by 112
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00746-3 · Cited by 87
Cited by
Fleischer, A., Kurth, S., Duell, J., Topp, M. S., Strunz, P., Mersi, J., Rasche, L., Sanges, C., Hudecek, M., Einsele, H., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009174 · Cited by 16
Zhang, Y., Gao, Z., Zhang, Y., Ai, S., Li, W., & Sun, L. (2025) · Biomolecules · doi:10.3390/biom15101375 · Cited by 6
“A recent Phase I dose-escalation study confirmed durable clinical activity of CD22 CAR-T (CAR22) in patients progressing after CD19 CAR-T therapy, validating CD22 as a salvage target for CAR-T-resistant lymphomas [173].”
Trends in non-Hodgkin lymphoma mortality: global, regional, and national insights from 1990 to 2021
Gu, F., & Zhang, L. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2522959
“Despite advancements in NHL treatment, including immunotherapy and targeted therapies, their global adoption remains uneven [9].”
Metadata
- Authors
- Schubert, M.-L., & Dreger, P.
- Affiliations
- Heidelberg University (DE)
- Corresponding author
- Dreger, Peter
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 404
- Issue
- 10450
- Pages
- 314-315
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4400440227
- Cited by
- 3
- References
- 13
- Citations by year
- 2025: 2 · 2024: 1
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University Hospital Heidelberg
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CD22, CAR T-cell therapy, large B-cell lymphoma, chimeric antigen receptor, hematologic malignancies, immunotherapy
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Sialic Acid Binding Ig-like Lectin 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00815-8
- The paper
- Schubert, M.-L., & Dreger, P. (2024). CD22 CAR T-cell therapy: new hope for patients with large B-cell lymphoma. The Lancet. https://doi.org/10.1016/s0140-6736(24)00815-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.